{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:43:08Z","timestamp":1780080188056,"version":"3.54.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>The emergence of effective direct\u2010acting antiviral (DAA) agents has reignited discussion over the potential for hepatitis C elimination in the United States. Eliminating hepatitis C will require a critical examination of technical feasibility, economic considerations, and social\/political attention. Tremendous advancement has been made with the availability of sensitive diagnostic tests and highly effective DAAs capable of achieving sustained viral response (SVR) in more than 95% of patients. Eliminating hepatitis C also requires escalating existing surveillance networks to monitor for new epidemics. All preventive interventions such as clean syringe and needle exchange programs, safe injection sites, opioid substitution therapies, and mental health services need to be expanded. Although costs of DAAs have raised budget concerns for hepatitis C elimination, studies have shown that eliminating hepatitis C will produce a savings of up to 6.5 billion USD annually along with other intangible benefits such as increased work productivity and quality of life. Economic models and meta\u2010analyses strongly suggest universal hepatitis C screening for all adults rather than just for birth cohort and high\u2010risk populations. Social and political factors are at least as important as technical feasibility and economic considerations. Due to lack of promotion and public awareness, HCV elimination efforts continue to receive inadequate funding. Social stigma continues to impede meaningful policy changes. Eliminating hepatitis C is an attainable public health goal that will require intense collaboration and sustained public support. (H<jats:sc>epatology<\/jats:sc> 2018;67:2449\u20102459).<\/jats:p>","DOI":"10.1002\/hep.29685","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T03:17:44Z","timestamp":1511839064000},"page":"2449-2459","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["Toward the elimination of hepatitis C in the United States"],"prefix":"10.1097","volume":"67","author":[{"given":"Sammy","family":"Saab","sequence":"first","affiliation":[{"name":"Department of Surgery,University of California Los Angeles,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Medicine,University of California Los Angeles,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satvir","family":"Saggi","sequence":"additional","affiliation":[{"name":"Olive View Medical Center,University of California Los Angeles,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Department of Medicine,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J.","family":"Tong","sequence":"additional","affiliation":[{"name":"Huntington Research Institute,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"hep29685-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmi.2016.07.035","article-title":"Hepatitis C: global epidemiology and strategies for control","volume":"22","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"hep29685-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence","volume":"31","year":"2011","journal-title":"Liver Int"},{"issue":"Suppl.","key":"hep29685-bib-0003-20241017","first-page":"S58","article-title":"Natural history of hepatitis C","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep29685-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","article-title":"Economic burden of hepatitis C infection","volume":"21","year":"2017","journal-title":"Clin Liver Dis"},{"key":"hep29685-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep29685-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta\u2010analysis of prevalence, quality of life, and economic burden","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl.","key":"hep29685-bib-0007-20241017","first-page":"S22","article-title":"The principles of disease elimination and eradication","volume":"76","year":"1998","journal-title":"Bull World Health Organ"},{"key":"hep29685-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra1200391","article-title":"Disease eradication","volume":"368","year":"2013","journal-title":"New Engl J Med"},{"key":"hep29685-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2105\/AJPH.90.10.1515","article-title":"When is a disease eradicable? 100 years of lessons learned","volume":"90","year":"2000","journal-title":"Am J Public Health"},{"key":"hep29685-bib-0013-20241017","first-page":"279","article-title":"The world's last endemic case of smallpox: surveillance and containment measures","volume":"58","year":"1980","journal-title":"Bull World Health Organ"},{"key":"hep29685-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"20130113","DOI":"10.1098\/rstb.2013.0113","article-title":"Lessons from the eradication of smallpox: an interview with D. A. Henderson","volume":"368","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"hep29685-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pmed.1000412","article-title":"Some lessons for the future from the Global Malaria Eradication Programme (1955\u20101969)","volume":"8","year":"2011","journal-title":"PLoS Med"},{"key":"hep29685-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","article-title":"Sensitivity and specificity of third\u2010generation hepatitis C virus antibody detection assays: an analysis of the literature","volume":"8","year":"2001","journal-title":"J Viral Hepat"},{"key":"hep29685-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"ofx109","DOI":"10.1093\/ofid\/ofx109","article-title":"Implementation of a large system\u2010wide hepatitis C virus screening and linkage to care program for baby boomers","volume":"4","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"hep29685-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3343\/alm.2013.33.3.184","article-title":"Performance evaluation of the OraQuick hepatitis C virus rapid antibody test","volume":"33","year":"2013","journal-title":"Ann Lab Med"},{"key":"hep29685-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"e0121450","DOI":"10.1371\/journal.pone.0121450","article-title":"Diagnostic accuracy of point\u2010of\u2010care tests for hepatitis C virus infection: a systematic review and meta\u2010analysis","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep29685-bib-0020-20241017","article-title":"Hepatitis C virus prevalence in Egyptian Americans in Southern California","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"hep29685-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta\u2010analysis","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep29685-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M14-0095","article-title":"The changing burden of hepatitis C virus infection in the United States: model\u2010based predictions","volume":"161","year":"2014","journal-title":"Ann Intern Med"},{"key":"hep29685-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost\u2010effectiveness of birth\u2010cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","year":"2012","journal-title":"Ann Intern Med"},{"key":"hep29685-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3201\/eid1509.081050","article-title":"Population\u2010based surveillance for hepatitis C virus, United States, 2006\u20102007","volume":"15","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"hep29685-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2014.07.015","article-title":"Can hepatitis C be eradicated in the United States?","volume":"110","year":"2014","journal-title":"Antiviral Res"},{"key":"hep29685-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","article-title":"Effectiveness of structural\u2010level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review","volume":"17","year":"2013","journal-title":"AIDS Behav"},{"key":"hep29685-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/474S18a","article-title":"Perspective: test and treat this silent killer","volume":"474","year":"2011","journal-title":"Nature"},{"key":"hep29685-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jama.1997.03540250061033","article-title":"Prevention of HIV\/AIDS and other blood\u2010borne diseases among injection drug users. A national survey on the regulation of syringes and needles","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"hep29685-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: a population\u2010based cohort study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl. 2","key":"hep29685-bib-0032-20241017","first-page":"S80","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta\u2010analysis","volume":"57","year":"2013","journal-title":"Clin Infect Dis"},{"key":"hep29685-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/nsr\/nwv040","article-title":"Hepatitis C virus vaccine development: old challenges and new opportunities","volume":"2","year":"2015","journal-title":"Natl Sci Rev"},{"key":"hep29685-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD\u2010IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep29685-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV\u20101 infection with early antiretroviral therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"hep29685-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale\u2010up in the age of direct\u2010acting antivirals","volume":"58","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"hep29685-bib-0038-20241017","first-page":"68","article-title":"HCV and HIV counseling and testing integration in California: an innovative approach to increase HIV counseling and testing rates","volume":"122","year":"2007","journal-title":"Public Health Rep"},{"key":"hep29685-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"e0164831","DOI":"10.1371\/journal.pone.0164831","article-title":"Hepatitis C virus screening and emergency department length of stay","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep29685-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community\u2010based nonspecialist providers: a nonrandomized clinical trial","volume":"167","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep29685-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jvh.12611","article-title":"Real\u2010world effectiveness for 12 weeks of ledipasvir\u2010sofosbuvir for genotype 1 hepatitis C: the Trio Health study","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep29685-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir\u2010sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep29685-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6629a2","article-title":"The role of screening and treatment in national progress toward hepatitis C elimination \u2013 Georgia, 2015\u20102016","volume":"66","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep29685-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies","volume":"9","year":"2017","journal-title":"Hepat Med"},{"key":"hep29685-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jvh.12671","article-title":"Impact of treatment on hepatitis C virus transmission and incidence in Egypt: a case for treatment as prevention","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep29685-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/epirev\/mxu002","article-title":"Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs","volume":"37","year":"2015","journal-title":"Epidemiol Rev"},{"key":"hep29685-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/cis011","article-title":"Cost\u2010effectiveness and population outcomes of general population screening for hepatitis C","volume":"54","year":"2012","journal-title":"Clin Infect Dis"},{"key":"hep29685-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/cid\/cit069","article-title":"Cost\u2010effectiveness of screening for chronic hepatitis C infection in the United States","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"key":"hep29685-bib-0051-20241017","doi-asserted-by":"crossref","first-page":"e011821","DOI":"10.1136\/bmjopen-2016-011821","article-title":"Cost\u2010effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations","volume":"6","year":"2016","journal-title":"BMJ Open"},{"key":"hep29685-bib-0052-20241017","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient\u2010reported outcomes: Results from the ION\u20101, \u20102, and \u20103 clinical trials","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep29685-bib-0053-20241017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cld.2006.08.026","article-title":"The economics of hepatitis C virus","volume":"10","year":"2006","journal-title":"Clin Liver Dis"},{"key":"hep29685-bib-0054-20241017","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep29685-bib-0055-20241017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of Hepatitis C by screening and treatment in United States prisons","volume":"164","year":"2016","journal-title":"Ann Intern Med"},{"key":"hep29685-bib-0056-20241017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining","volume":"129","year":"2014","journal-title":"Public Health Rep"},{"key":"hep29685-bib-0057-20241017","article-title":"Hepatitis testing and treatment in state prisons","year":"2004","journal-title":"Bur Justice Stat Spec Rep"},{"key":"hep29685-bib-0058-20241017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2105\/AJPH.2014.302071","article-title":"Survey of US correctional institutions for routine HCV testing","volume":"105","year":"2015","journal-title":"Am J Public Health"},{"key":"hep29685-bib-0059-20241017","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","article-title":"Direct\u2010acting antiviral agents for patients with Hepatitis C virus genotype 1 infection are cost\u2010saving","volume":"15","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep29685-bib-0060-20241017","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost\u2010effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep29685-bib-0063-20241017","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.21565","article-title":"The effects of HCV infection and management on health\u2010related quality of life","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep29685-bib-0064-20241017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cld.2017.03.001","article-title":"Hepatitis C infection: a systemic disease","volume":"21","year":"2017","journal-title":"Clin Liver Dis"},{"key":"hep29685-bib-0065-20241017","doi-asserted-by":"crossref","first-page":"e5914","DOI":"10.1097\/MD.0000000000005914","article-title":"Superiority of interferon\u2010free regimens for chronic hepatitis C: the effect on health\u2010related quality of life and work productivity","volume":"96","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"hep29685-bib-0066-20241017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient\u2010reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus\u2010related decompensated cirrhosis: an exploratory analysis from the randomised, open\u2010label ASTRAL\u20104 phase 3 trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep29685-bib-0067-20241017","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all\u2010cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"hep29685-bib-0068-20241017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","year":"2015","journal-title":"BMC Infect Dis"},{"key":"hep29685-bib-0069-20241017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.278.5335.45","article-title":"Additiction is a brain disease, and it matters","volume":"278","year":"1997","journal-title":"Science"},{"key":"hep29685-bib-0070-20241017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2850.1996.tb00127.x","article-title":"An extended literature review of health professionals' perceptions of illicit drugs and their clients who use them","volume":"3","year":"1996","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"hep29685-bib-0071-20241017","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1525-1497.2003.20826.x","article-title":"They treated me like a leper\u201d: Stigmatization and the quality of life of patients with hepatitis C","volume":"18","year":"2003","journal-title":"J Gen Intern Med"},{"key":"hep29685-bib-0072-20241017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/pubmed\/fdl090","article-title":"Changes in injecting practices associated with the use of a medically supervised safer injection facility","volume":"29","year":"2007","journal-title":"J Public Health (Oxf)"},{"key":"hep29685-bib-0074-20241017","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.39113.402361.94","article-title":"Are we spending too much on HIV?","volume":"334","year":"2007","journal-title":"BMJ"},{"key":"hep29685-bib-0078-20241017","first-page":"1201","article-title":"Prevalence and awareness of HIV infection among men who have sex with men \u2010\u2010\u2010 21 cities, United States, 2008","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201806000-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:33:04Z","timestamp":1729211584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201806000-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29685","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"2017-09-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}